photosensitizer

(redirected from Photosensitiser)
Also found in: Medical, Encyclopedia.

pho·to·sen·si·tize

 (fō′tō-sĕn′sĭ-tīz′)
tr.v. pho·to·sen·si·tized, pho·to·sen·si·tiz·ing, pho·to·sen·si·tiz·es
To make (an organism, a cell, or a substance) photosensitive.

pho′to·sen′si·tiz′er n.

photosensitizer

(ˌfəʊtəʊˈsɛnsɪˌtaɪzə) or

photosensitiser

n
(Pharmacology) pharmacol US a drug, food, or other chemical that increases sensitivity to light and other visible photons
Translations
photosensibilisateur
References in periodicals archive ?
The subject of the tender is the delivery time resolved spectrofluorimeter, allowing the detection of luminescence with high temporal and spectral resolution, with emphasis on the possibility of direct detection of singlet oxygen (1270 nm) and singlet oxygen sensitized delayed fluorescence porfyrinoidnE[degrees]ch photosensitiser (600-700 nm).
Methyl 5- aminolevulinate was used as the photosensitiser and only two treatments were given, one week apart.
The alternative is to develop the proprietary photosensitiser Amphinex in combination with the cytotoxic agent bleomycin for treatment of head and neck cancer.
The research team -- from the University of Hull's Department of Chemistry -- placed one kind of photosensitiser inside each nanoparticle and another on the outside, which meant that far more reactive oxygen species could be created from the same amount of light.
The last patient has been treated with the company's proprietary photosensitiser Amphinex used in combination with the cytotoxic agent bleomycin at University College Hospital (UCH) in London.
The cells were incubated in dark in 96-well plates with different concentrations of the Sn(IV) chlorin e6 photosensitiser (10, 15, 20, 25 and 30 [micro]g/ml) and was not treated with light.
The last patient has been treated with the company's proprietary photosensitiser Amphinex[R] used in combination with the cytotoxic agent bleomycin at University College Hospital (UCH) in London.
In this review, recent developments in photosensitiser families are discussed with respect to in vitro performance indicators and to potential application in oncology.
17 March 2010 - Norwegian biopharmaceutical company PCI Biotech (OSL: PCIB) reported yesterday that it has completed the treatment of the third dose group in the Phase I/II study of its proprietary photosensitiser Amphinex used in combination with the cytotoxic agent bleomycin in cancer patients.